Session » (1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1241

Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort

9:00AM-11:00AM: Abstract Number: 1242

Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1235

Apparent Diffusion Coefficient (ADC) from Diffusion Weighted Imaging (DWI) as an Objective Tool to Differentiate Normal Maturational Subchondral Signal from Inflammation at the Sacroiliac Joint in Youth

9:00AM-11:00AM: Abstract Number: 1246

Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis

9:00AM-11:00AM: Abstract Number: 1244

Characterizing Lupus in African American Children in Southern United States

9:00AM-11:00AM: Abstract Number: 1255

Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1239

Clinical Manifestations and Management of Takayasu Arteritis: A Multicenter Pediatric Cohort

9:00AM-11:00AM: Abstract Number: 1234

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity

9:00AM-11:00AM: Abstract Number: 1249

Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1230

Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive

9:00AM-11:00AM: Abstract Number: 1245

Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 1226

Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1223

Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis

9:00AM-11:00AM: Abstract Number: 1221

Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 1232

Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 1250

Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis

9:00AM-11:00AM: Abstract Number: 1229

Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus

9:00AM-11:00AM: Abstract Number: 1236

Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1224

Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic

9:00AM-11:00AM: Abstract Number: 1225

Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 1251

Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital

9:00AM-11:00AM: Abstract Number: 1240

Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash

9:00AM-11:00AM: Abstract Number: 1254

Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)

9:00AM-11:00AM: Abstract Number: 1247

Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial

9:00AM-11:00AM: Abstract Number: 1252

Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?

9:00AM-11:00AM: Abstract Number: 1238

Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1227

Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1231

Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1222

The Association Between Gingival Inflammation and Clinical Signs of Active Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 1237

The Associations Between Depressive Symptoms and Executive Function and Academic Outcomes in Children with SLE

9:00AM-11:00AM: Abstract Number: 1253

The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 1233

The Pattern of Medication Use Significantly Changed over 36 Months Observation Period. Result from the Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 1248

Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry

9:00AM-11:00AM: Abstract Number: 1243

Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1228

Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].